BACKGROUND: Silicosis is an occupational lung disease characterized by inflammation and fibrosis. As it is irreversible, early identification of high-risk individuals is clinically important, but biomarkers for progression remain lacking. PURPOSE: To determine whether ventilation and perfusion defects quantified by phase-resolved functional lung (PREFUL) MRI can predict silicosis progression. STUDY TYPE: Prospective. SUBJECTS: Thirty participants with silicosis (29 males and 1 female) and 30 healthy controls (29 males and 1 female). SEQUENCE: 2D spoiled gradient echo, 3.0 T. ASSESSMENT: All participants underwent baseline PREFUL MRI, pulmonary function tests (PFTs), and chest CT, with quantitative calculation of ventilation defect percentages (VDP(RVent) and VDP(FVL-CM)) and perfusion defect percentage (QDP). Silicosis was followed for 1 year with assessments including forced vital capacity percent predicted (FVC% predicted), diffusing capacity of the lungs for carbon monoxide percent predicted (DL(co)% predicted), symptoms, and CT. Disease progression was defined by any two of: (a) CT evidence of progression, (b) worsening symptoms, or (c) >/= 10% decline in FVC% predicted or >/= 15% decline in DLco% predicted. STATISTICAL TESTS: Spearman correlation coefficients were used to evaluate the correlation between ventilation/perfusion metrics and PFT parameters. Receiver operating characteristic (ROC) curves were used to assess the ability of PREFUL MRI parameters to classify disease progression, reporting the area under the curve (AUC), sensitivity, and specificity. Significance was set at p < 0.05. RESULTS: Eight patients progressed and 22 remained stable. Baseline VDP(RVent), VDP(FVL-CM), and QDP were significantly higher in progressors (36%, 34%, 40%) than in non-progressors (22%, 15%, 22%). QDP showed strong predictive performance with AUC of 0.72 (95% CI: 0.51-0.93) for radiological progression, 0.90 (95% CI: 0.79-1.00) for PFTs decline, and 0.97 (95% CI: 0.92-1.00) for global progression. DATA CONCLUSION: Increased ventilation and perfusion defects on PREFUL MRI are associated with silicosis progression. EVIDENCE LEVEL: 2. TECHNICAL EFFICACY: Stage 2. TRIAL REGISTRATION: NCT06431555. Silicosis is an irreversible lung disease, and distinguishing patients with progressive from stable forms remains challenging. This study used a non-contrast imaging technique called phase-resolved functional lung MRI (PREFUL MRI) to follow 30 patients with silicosis over time. The results showed that ventilation and perfusion parameters measured by PREFUL MRI could accurately differentiate progressive from non-progressive cases, with an AUC of 0.97. These findings suggest that PREFUL MRI offers a promising, noninvasive tool for early prediction of silicosis progression. eng
Keywords
